DDInter1926 DDInter1752
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries. Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax. Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells. A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have
Drug-resistant bacteria, such as methicillin-resistant _Staphylococcus aureus_, vancomycin-resistant _Enterococcus faecium_, and penicillin-resistant _Streptococcus penumoniae_, represent a massive public health threat.[A199086, A199131] Tedizolid is a member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than [linezolid].[L11232, A199086, A199050] Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO®). This product is currently available as both an oral tablet and as a powder for intravenous injection.
Venetoclax {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Venetoclax {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secobarbital
Venetoclax {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Erdafitinib
Venetoclax {u} may lead to a major life threatening interaction when taken with {v} Atazanavir
Venetoclax {u} may lead to a major life threatening interaction when taken with {v} Lorlatinib
Venetoclax may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
Venetoclax may lead to a major life threatening interaction when taken with Atazanavir
Venetoclax may lead to a major life threatening interaction when taken with Lorlatinib